{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:40:57Z","timestamp":1791592857228,"version":"4.3.4"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007453","name":"VERUM Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007453","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Sheffield National Institute for Health Research"},{"name":"Biomedical Research Centre"},{"name":"University of Cambridge\u2014Ludwig-Maximilians-University Munich Strategic Partnership"},{"name":"Hector II Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>After years of failed attempts to develop a disease-modifying therapy for Alzheimer\u2019s disease, consistent evidence in support of clinical efficacy was finally presented for a monoclonal antibody targeting the amyloid-\u03b2 protofibrils. In addition to meeting the primary outcome of slowing clinical disease progression over 18 months, secondary clinical outcomes and amyloid-\u03b2 lowering on PET also underpin the positive results of the trial.<\/jats:p>\n                  <jats:p>In this opinion piece, we highlight the key characteristics of the previous unsuccessful trials and analyse the potential reasons why those attempts to develop a treatment for early Alzheimer\u2019s disease failed. We compare the safety profiles of the different antibodies and highlight cautionary measures for their routine clinical use. Last, we discuss the role of blood-based biomarkers in transforming the clinical care pathway to facilitate the uptake of antibody treatments, proposing an integrated case-finding and treatment model crossing the different healthcare sectors.<\/jats:p>\n                  <jats:p>Taken together, a real breakthrough may have been achieved by proving that amyloid-\u03b2 reduction results in clinical benefits, rather than just biomarker changes. At the same time, routine use of the new generation of drugs will show if statistical efficacy translates into clinically meaningful change. This may just be the beginning of a new era of Alzheimer\u2019s disease drug development.<\/jats:p>","DOI":"10.1093\/brain\/awad005","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T15:17:45Z","timestamp":1673277465000},"page":"842-849","source":"Crossref","is-referenced-by-count":180,"title":["Anti-amyloid antibody therapies in Alzheimer\u2019s disease"],"prefix":"10.1093","volume":"146","author":[{"given":"Robert","family":"Perneczky","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich , Munich 80336 , Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE) Munich , Munich 81377 , Germany"},{"name":"Munich Cluster for Systems Neurology (SyNergy) , Munich 81377 , Germany"},{"name":"Ageing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London , London W6 8RP , UK"},{"name":"Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield , Sheffield S10 2HQ , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Jessen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University of Cologne , Cologne 50937 , Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE) Bonn , Bonn 53127 , Germany"},{"name":"Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne , 50937 Cologne , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Grimmer","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technical University of Munich, School of Medicine , Munich 81675 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Levin","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases (DZNE) Munich , Munich 81377 , Germany"},{"name":"Munich Cluster for Systems Neurology (SyNergy) , Munich 81377 , Germany"},{"name":"Department of Neurology, University Hospital, LMU Munich , Munich 81377 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Fl\u00f6el","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Medicine Greifswald , Greifswald 17475 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Peters","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Charit\u00e9, Campus Benjamin Franklin , Berlin 12203 , Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE) Berlin , Berlin 10117 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Froelich","sequence":"additional","affiliation":[{"name":"Department of Geriatric Psychiatry, Central Institute of Mental Health , Mannheim 68159 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"key":"2023030117462485100_","author":"Prince","year":"2015"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"e12295","DOI":"10.1002\/trc2.12295","article-title":"Alzheimer\u2019s disease drug development pipeline: 2022","volume":"8","author":"Cummings","year":"2022","journal-title":"Alzheimers Dement (N Y)"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13195-018-0424-5","article-title":"Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer\u2019s disease (BLAZE)","volume":"10","author":"Salloway","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13195-019-0559-z","article-title":"Gantenerumab reduces amyloid-beta plaques in patients with prodromal to moderate Alzheimer\u2019s disease: A PET substudy interim analysis","volume":"11","author":"Klein","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"2023030117462485100_","first-page":"414","article-title":"Donanemab (LY3002813) phase 1b study in Alzheimer\u2019s disease: Rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging","volume":"8","author":"Lowe","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/alz.12379","article-title":"Bayes Analysis supports null hypothesis of anti-amyloid beta therapy in Alzheimer\u2019s disease","volume":"17","author":"Richard","year":"2021","journal-title":"Alzheimers Dement"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2022","journal-title":"N Engl J Med"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1038\/s41598-018-24501-0","article-title":"Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-beta","volume":"8","author":"Arndt","year":"2018","journal-title":"Sci Rep"},{"key":"2023030117462485100_"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"2023030117462485100_"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): Current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"key":"2023030117462485100_","first-page":"151","article-title":"Psychometric properties of the Clinical Dementia Rating\u2014sum of boxes and other cognitive and functional outcomes in a prodromal Alzheimer\u2019s disease population","volume":"8","author":"McDougall","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"2023030117462485100_","first-page":"197","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Haeberlein S","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.3174\/ajnr.A3500","article-title":"MR Imaging features of amyloid-related imaging abnormalities","volume":"34","author":"Barakos","year":"2013","journal-title":"AJNR Am J Neuroradiol"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1056\/NEJMp2204487","article-title":"Accelerated approval\u2014taking the FDA\u2019s concerns seriously","volume":"387","author":"Sachs","year":"2022","journal-title":"N Engl J Med"},{"key":"2023030117462485100_"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nn0901-887","article-title":"The \u2018Arctic\u2019 APP mutation (E693G) causes Alzheimer\u2019s disease by enhanced Abeta protofibril formation","volume":"4","author":"Nilsberth","year":"2001","journal-title":"Nat Neurosci"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.nbd.2009.08.007","article-title":"An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer\u2019s disease","volume":"36","author":"Lord","year":"2009","journal-title":"Neurobiol Dis"},{"key":"2023030117462485100_"},{"issue":"Suppl 2","key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/00002093-199700112-00003","article-title":"Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer\u2019s Disease Assessment Scale that broaden its scope. The Alzheimer\u2019s Disease Cooperative Study","volume":"11","author":"Mohs","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/ageing\/afj054","article-title":"Complex activities of daily living in mild cognitive impairment: Conceptual and diagnostic issues","volume":"35","author":"Perneczky","year":"2006","journal-title":"Age Ageing"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/gps.1444","article-title":"Impairment of activities of daily living requiring memory or complex reasoning as part of the MCI syndrome","volume":"21","author":"Perneczky","year":"2006","journal-title":"Int J Geriatr Psychiatry"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1001\/archneurol.2011.150","article-title":"Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease","volume":"68","author":"Fleisher","year":"2011","journal-title":"Arch Neurol"},{"key":"2023030117462485100_"},{"key":"2023030117462485100_"},{"key":"2023030117462485100_","article-title":"Second death linked to potential antibody treatment for Alzheimer\u2019s disease","author":"Piller","year":"27 2022","journal-title":"Science"},{"key":"2023030117462485100_","author":"Pillar","year":"21 2022. 31 2023"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1126\/science.1078259","article-title":"Cerebral hemorrhage after passive anti-Abeta immunotherapy","volume":"298","author":"Pfeifer","year":"2022","journal-title":"Science"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/JAD-2011-110977","article-title":"Gantenerumab: A novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta","volume":"28","author":"Bohrmann","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrd4363","article-title":"Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies","volume":"13","author":"Mitragotri","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/jama.2021.15286","article-title":"Representativeness of participants eligible to be enrolled in clinical trials of aducanumab for Alzheimer disease compared with medicare beneficiaries with Alzheimer disease and mild cognitive impairment","volume":"326","author":"Anderson","year":"2021","journal-title":"JAMA"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1523\/JNEUROSCI.0503-19.2019","article-title":"Sleep as a potential biomarker of tau and beta-amyloid burden in the human brain","volume":"39","author":"Winer","year":"2019","journal-title":"J Neurosci"},{"key":"2023030117462485100_"},{"key":"2023030117462485100_","first-page":"2","article-title":"Assessing the preparedness of the health care system infrastructure in six European countries for an Alzheimer\u2019s treatment","volume":"8","author":"Hlavka","year":"2019","journal-title":"Rand Health Q"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jama.2009.1064","article-title":"CSF Biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment","volume":"302","author":"Mattsson","year":"2009","journal-title":"JAMA"},{"issue":"Suppl 8","key":"2023030117462485100_","article-title":"The Oxford Brain Health Centre: Embedding dementia research in clinical practice","volume":"16","author":"O\u2019Donoghue","year":"2020","journal-title":"Alzheimers Dement"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","article-title":"Performance of plasma phosphorylated tau 181 and 217 in the community","volume":"28","author":"Mielke","year":"2022","journal-title":"Nat Med"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jalz.2016.09.008","article-title":"Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia","volume":"13","author":"Simonsen","year":"2017","journal-title":"Alzheimers Dement"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jalz.2013.01.002","article-title":"Appropriate use criteria for amyloid PET: A report of the amyloid imaging task force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer\u2019s Association","volume":"9","author":"Johnson","year":"2013","journal-title":"Alzheimers Dement"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/alz.12756","article-title":"The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease","volume":"18","author":"Hansson","year":"2022","journal-title":"Alzheimers Dement"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"2023030117462485100_","doi-asserted-by":"crossref","first-page":"e12271","DOI":"10.1002\/trc2.12271","article-title":"Frequency of missed or delayed diagnosis in dementia is associated with neighborhood socioeconomic status","volume":"8","author":"Holm","year":"2022","journal-title":"Alzheimers Dement (N Y)"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awad005\/49215535\/awad005.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/146\/3\/842\/49356223\/awad005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/146\/3\/842\/49356223\/awad005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T18:02:22Z","timestamp":1728669742000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/146\/3\/842\/6991820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,1,19]]},"published-print":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awad005","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2023,1,19]]}}}